Shigematsu Y - Search Results

1

Immunotherapy Benefit Over Best Supportive Care in Hepatocellular Cancer With Child-Pugh B Dysfunction.

Shigematsu Y. Shigematsu Y. JAMA Oncol. 2024 Dec 26. doi: 10.1001/jamaoncol.2024.5813. Online ahead of print. JAMA Oncol. 2024. PMID: 39724397 No abstract available.

2

High Levels of Antidrug Antibodies Against Atezolizumab as a Predictive Marker for Clinical Outcomes in Patients With Hepatocellular Carcinoma.

Shigematsu Y, Inamura K. Shigematsu Y, et al. JAMA Oncol. 2023 May 1;9(5):725. doi: 10.1001/jamaoncol.2023.0108. JAMA Oncol. 2023. PMID: 36928513 No abstract available.

3

Machine Learning-Based Treatment Allocation for Recurrent Hepatocellular Carcinoma.

Shigematsu Y, Inamura K. Shigematsu Y, et al. JAMA Surg. 2023 Oct 1;158(10):1113-1114. doi: 10.1001/jamasurg.2023.1673. JAMA Surg. 2023. PMID: 37256581 No abstract available.

4

Gut microbiome: a key player in cancer immunotherapy.

Shigematsu Y, Inamura K. Shigematsu Y, et al. Hepatobiliary Surg Nutr. 2018 Dec;7(6):479-480. doi: 10.21037/hbsn.2018.10.02. Hepatobiliary Surg Nutr. 2018. PMID: 30652093 Free PMC article. No abstract available.

5

The need to optimize chemotherapy regimens for chemo-immunotherapy.

Inamura K, Shigematsu Y. Inamura K, et al. Among authors: shigematsu y. J Thorac Dis. 2022 Sep;14(9):3648-3649. doi: 10.21037/jtd-22-1101. J Thorac Dis. 2022. PMID: 36245594 Free PMC article. No abstract available.

6

Identification of a DNA methylation marker that detects the presence of lymph node metastases of gastric cancers.

Shigematsu Y, Niwa T, Yamashita S, Taniguchi H, Kushima R, Katai H, Ito S, Tsukamoto T, Ichinose M, Ushijima T. Shigematsu Y, et al. Oncol Lett. 2012 Aug;4(2):268-274. doi: 10.3892/ol.2012.708. Epub 2012 May 9. Oncol Lett. 2012. PMID: 22844368 Free PMC article.

7

EGFR-Mutated Pulmonary Choriocarcinoma Combined With Adenocarcinoma.

Shigematsu Y, Nakano K, Uchibori K, Inamura K. Shigematsu Y, et al. J Thorac Oncol. 2022 Nov;17(11):1318-1322. doi: 10.1016/j.jtho.2022.07.1146. Epub 2022 Aug 10. J Thorac Oncol. 2022. PMID: 35963570 Free article. No abstract available.

8

Is machine learning-based assessment of tumor-infiltrating lymphocytes on standard histologic images associated with outcomes of immunotherapy in patients with NSCLC?

Inamura K, Shigematsu Y. Inamura K, et al. Among authors: shigematsu y. J Thorac Dis. 2023 May 30;15(5):2882-2884. doi: 10.21037/jtd-22-1862. Epub 2023 Apr 23. J Thorac Dis. 2023. PMID: 37324072 Free PMC article. No abstract available.

9

Schistosoma japonicum-related hepatitis: potential contributor to hepatocellular carcinoma.

Kato S, Shigematsu Y, Saito R, Ito H, Inamura K. Kato S, et al. Among authors: shigematsu y. QJM. 2024 Oct 1;117(10):737-738. doi: 10.1093/qjmed/hcae116. QJM. 2024. PMID: 38867695 No abstract available.

10

Relationships between tumor CD147 expression, tumor-infiltrating lymphocytes, and oncostatin M in hepatocellular carcinoma.

Shigematsu Y, Kanda H, Takahashi Y, Takeuchi K, Inamura K. Shigematsu Y, et al. Virchows Arch. 2024 Oct 12. doi: 10.1007/s00428-024-03939-w. Online ahead of print. Virchows Arch. 2024. PMID: 39395054

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

570 results

Search Page

Filters